Titan Pharmaceuticals, Inc. (TTNP)

NASDAQ: TTNP · IEX Real-Time Price · USD
6.95
-0.34 (-4.66%)
Mar 28, 2024, 2:30 PM EDT - Market open
-4.66%
Market Cap 5.96M
Revenue (ttm) 306,000
Net Income (ttm) -6.17M
Shares Out 753.32K
EPS (ttm) -8.20
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,178
Open 7.00
Previous Close 7.29
Day's Range 6.95 - 7.32
52-Week Range 5.00 - 17.00
Beta 1.34
Analysts n/a
Price Target n/a
Earnings Date May 13, 2024

About TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 18, 1996
Employees 4
Stock Exchange NASDAQ
Ticker Symbol TTNP
Full Company Profile

Financial Performance

In 2022, TTNP's revenue was $557,000, a decrease of -63.50% compared to the previous year's $1.53 million. Losses were -$10.21 million, 16.3% more than in 2021.

Financial Statements

News

Titan Pharmaceuticals Fully Compliant With NASDAQ Listing Criteria

SOUTH SAN FRANCISCO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that by letter dated January 24, 2024, the Company ...

2 months ago - GlobeNewsWire

Titan Pharmaceuticals Announces Reverse Stock Split and Ratio

SOUTH SAN FRANCISCO, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) today announced that its Board of Directors has approved a 1-for-20...

3 months ago - GlobeNewsWire

Titan Pharmaceuticals Announces Appointment of Dato' Seow Gim Shen and Brynner Chaim to the Company's Board of Directors

SAN FRANCISCO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to announce the appointments of Dato' Seow Gim Shen and Brynner Chiam ...

5 months ago - GlobeNewsWire

Titan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock

SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreem...

6 months ago - GlobeNewsWire

Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets

Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net sales Company to receive $2 mil...

8 months ago - GlobeNewsWire

Titan Pharmaceuticals Provides Shareholder Update

SAN FRANCISCO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") is pleased to report that it has entered a non-binding letter of intent to comple...

1 year ago - GlobeNewsWire

UPDATE -- Titan Pharmaceuticals Inc. Announces Licensing Agreement with Ocular Therapeutix Inc.

SAN FRANCISCO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has granted an exclusive license to Ocular Therapeutix In...

1 year ago - GlobeNewsWire

Titan Pharmaceuticals Announces Board Expansion and Management Changes

SOUTH SAN FRANCISCO, Calif. , Aug. 16, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has expanded its Board of Directors (the "Boar...

1 year ago - PRNewsWire

Titan Pharmaceuticals Announces FDA Clearance of IND Application for Nalmefene Implant

SOUTH SAN FRANCISCO, Calif. , July 5, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that the U.S. Food and Drug Administration ("FDA") has ...

1 year ago - PRNewsWire

Activist Investing Discloses 9.9% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- David E. Lazar, Chief Executive Officer of Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), one of the largest stockhold...

1 year ago - GlobeNewsWire

Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc.

NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Activist Investing LLC (together with its affiliates, “Activist Investing” or “we”), today filed a Schedule 13D announcing its acquisition of approximately...

2 years ago - GlobeNewsWire

Titan Pharmaceuticals Raises $5.5M Via Equity

Titan Pharmaceuticals Inc TTNP has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. Thousands of new traders are learning the ins and outs on how to find prof...

2 years ago - Benzinga

Titan Pharmaceuticals Announces Pricing of $5.5 Million Registered Direct and PIPE Offering Priced At-The-Market

SOUTH SAN FRANCISCO, Calif., Feb. 2, 2022 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a securities purchase agreement...

2 years ago - PRNewsWire

Titan Pharmaceuticals to Explore Strategic Alternatives

SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has commenced a process to explore and evaluate...

2 years ago - PRNewsWire

Sustained Anti-Pruritic Effect Of Titan's TP-2021 Implant Reported Today At Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Nov. 8, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced that, in a presentation given today at the Society for Neurosc...

2 years ago - PRNewsWire

Titan Announces Upcoming TP-2021 Implant Data Presentation at Neuroscience 2021

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. announced that data from continuing studies of its ProNeura®-based TP-2021 implant in an established animal model ...

2 years ago - PRNewsWire

Titan Pharmaceuticals Receives Funding to Develop Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries

SOUTH SAN FRANCISCO, Calif., Oct. 25, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received funding from the Bill & Melinda Ga...

2 years ago - PRNewsWire

Titan Pharmaceuticals and MUSC FRD Enter Into Research and Option License Agreement

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a research and option license ...

2 years ago - PRNewsWire

Titan Announces Positive Results from the First Studies of TP-2021 Implant in an Established Animal Model of Chronic Pruritus

SOUTH SAN FRANCISCO, Calif., June 23, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that the in vivo study of its human kappa-opioid receptor agonist ("TP-2021," form...

3 years ago - PRNewsWire

Titan Pharmaceuticals Announces Filing Of 2020 Annual Report On Form 10-K

SOUTH SAN FRANCISCO, Calif., March 31, 2021 /PRNewswire/ --  Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that it has filed its annual report on Form 10-K for the fiscal year ended Decem...

3 years ago - PRNewsWire

Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program

SOUTH SAN FRANCISCO, Calif., Feb. 1, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that studies of its kappa opioid agonist peptide, JT-09, has demonstrated high pote...

3 years ago - PRNewsWire

Titan Pharmaceuticals Announces Pricing of $9.7 Million Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2021 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited instit...

3 years ago - PRNewsWire

Titan Pharmaceuticals Announces Reverse Stock Split

SOUTH SAN FRANCISCO, Calif., Nov. 30, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that its Board of Directors has approved a 1-for-30 rev...

3 years ago - PRNewsWire

Titan Pharmaceuticals Reports Third Quarter 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the third quarter ended September ...

3 years ago - PRNewsWire

Titan Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced the pricing of an underwritten public offering of 80,000,000 units at a price of $...

3 years ago - PRNewsWire